<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307020</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-TRA 02</org_study_id>
    <secondary_id>2010-022798-32</secondary_id>
    <nct_id>NCT01307020</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain</brief_title>
  <acronym>DEX-TRA 02</acronym>
  <official_title>Double-blind, Randomised, Placebo and Active Controlled, Parallel Group Study to Evaluate the Analgesic Effect of a Single Oral Administration of Four Different Combination Doses of DKP.TRIS With TRAM.HCL in Comparison With the Single Agents, on Moderate to Severe Pain Following Impacted Third Mandibular Molar Tooth Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the analgesic efficacy of Dexketoprofen Trometamol
      and Tramadol Hydrochloride given in combinations and the analgesic efficacy of each single
      component in comparison to placebo on moderate to severe pain following impacted third
      mandibular molar tooth extraction. Ibuprofen will be used as an active control to validate
      the pain model.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to develop a combination of Dexketoprofen Trometamol (DKP.TRIS) and
      Tramadol Hydrochloride (TRAM.HCl) for the treatment of acute moderate to severe pain, based
      on the rationale that more than one drug is necessary in most patients suffering of acute and
      chronic pain, particularly of moderate to severe intensity.

      DKP.TRIS and TRAM.HCl have different mechanisms of action, therefore their combination is
      expect to result in an additive or synergistic analgesia, thus allowing a decrease in the
      required doses of the individual agents, and consequently a reduced risk of adverse events In
      this study, patients who present moderate to severe pain after impacted third mandibular
      molar tooth extraction will be randomised to a total of 10 treatment arms including 4
      combinations of DKP.TRIS + TRAM.HCl, the four corresponding single treatments, placebo and
      ibuprofen. Treatment administration will be followed by a 24-hour pain and analgesic effect
      assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.</measure>
    <time_frame>6 hours</time_frame>
    <description>Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.</measure>
    <time_frame>4, 8 and 12 hours</time_frame>
    <description>Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 4, 8 and 12 hours(maxTOTPAR4h= 16, maxTOTPAR8h= 32 and maxTOTPAR12h= 48, respectively) Unit of measure is %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Using Rescue Medication at 6 Hours</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>Percentage of patients using rescue medication at 6 hours post-dosing.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">745</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TRAM.HCl high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TRAM.HCl low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DKP-TRIS high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DKP-TRIS low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DKP-TRIS low dose - TRAM.HCl low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DKP-TRIS low dose - TRAM.HCl high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DKP-TRIS high dose - TRAM.HCl low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DKP-TRIS high dose - TRAM.HCl high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen Trometamol</intervention_name>
    <description>Dexketoprofen Trometamol low dose, oral film-coated table, once</description>
    <arm_group_label>DKP-TRIS low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen Trometamol</intervention_name>
    <description>Dexketoprofen Trometamol high dose, oral film-coated table, once</description>
    <arm_group_label>DKP-TRIS high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Hydrochloride</intervention_name>
    <description>Tramadol Hydrochloride low dose, oral film-coated table, once</description>
    <arm_group_label>TRAM.HCl low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Hydrochloride</intervention_name>
    <description>Tramadol Hydrochloride high dose, oral film-coated table, once</description>
    <arm_group_label>TRAM.HCl high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 400 mg, oral film-coated table, once</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, oral film-coated table, once</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen Trometamol + Tramadol Hydrochloride</intervention_name>
    <description>DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once</description>
    <arm_group_label>DKP-TRIS low dose - TRAM.HCl low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen Trometamol + Tramadol Hydrochloride</intervention_name>
    <description>DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once</description>
    <arm_group_label>DKP-TRIS low dose - TRAM.HCl high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen Trometamol + Tramadol Hydrochloride</intervention_name>
    <description>DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once</description>
    <arm_group_label>DKP-TRIS high dose - TRAM.HCl low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen Trometamol + Tramadol Hydrochloride</intervention_name>
    <description>DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once</description>
    <arm_group_label>DKP-TRIS high dose - TRAM.HCl high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients meeting ALL the following criteria will be eligible for entry into the study:

          -  Male or female patients aged 18 to 70 years old. Females participating in the study
             must be either: of non-childbearing potential, or willing to use a highly effective
             contraceptive method.

          -  Scheduled for outpatient surgical extraction -under local anaesthesia- of third
             mandibular molar teeth, with at least one of which is fully or partially impacted in
             the mandible requiring bone manipulation.

          -  Normal physical examination or without clinically relevant abnormalities.

        At randomisation (after surgery):

        No intake of analgesics (including prescription and over the counter drugs) within 24h
        prior to the surgery.

          -  No complication during the surgery, duration of surgery &lt; 1 hour and not requiring
             re-anaesthesia.

          -  Patients experiencing pain of moderate or higher intensity in the first four hours
             after the end of surgery.

        Exclusion Criteria:

          -  History of allergy or hypersensitivity to NSAIDs, opioids or acetyl salicylic acid.

          -  History of asthma, bronchospasm, acute rhinitis, nasal polyps, urticaria or
             angioneurotic oedema.

          -  History of peptic ulcer, gastrointestinal disorders by NSAIDs, gastrointestinal
             bleeding or other active bleedings.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cosme Gay-Escoda, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Barcelona - Bellvitge Institute for Biomedical Research (IDIBELL) 08907 Hospitalet de Llobregat, Barcelona (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R Andrew Moore, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Pain Research &amp; Nuffield Division of Anaesthesics, Department of Clinical Neurosciences, University of Oxford. The Churchill, Oxford OX3 7LJ (United Kingdom)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik und Polickinik für Mund-Kiefer-Gesichtschirurgie/Plastische Operationen Greifswald</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum Schleswig Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Tóth Bagi Zoltán Fogászati Rendeloje</name>
      <address>
        <city>Budapest</city>
        <zip>1052</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Farmacologia Clinica per la Sperimentazione dei Farmaci</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Ricerche Cliniche di Verona Srl. Policlinico G.B.Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Stomatologiczny Andrzej Wojtowicz AW Clinic</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-852</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dental Service spólka jawna</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-791</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Médico Quirúrgico de Conxo</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facultad de Odontología. Departamento de Cirugía Bucal y Maxilofacial, University of Barcelona - Bellvitge Institute for Biomedical Research (IDIBELL)</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Complutense de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departamento de Estomatología, Facultad de Odontología. Universidad de Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departament d'Estomatologia, Clínica Odontològica, Universidad de Valencia - Fundació Lluís Alcanyís</name>
      <address>
        <city>Valencia</city>
        <zip>046010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The School of Dentistry, College of Medical and Dental Sciences, University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6 NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Dental School Manchester</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M15 6FH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Dental Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4 XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <results_first_submitted>October 11, 2012</results_first_submitted>
  <results_first_submitted_qc>November 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2012</results_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe pain</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Dexketoprofen</keyword>
  <keyword>Tramadol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Dexketoprofen trometamol</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient in (screening) 23 Feb 2011, last patient out 14 Oct 2011. At 16 study centres in 6 European countries (Germany, Italy, Hungary, Poland, Spain and United Kingdom).</recruitment_details>
      <pre_assignment_details>The trial encompassed 3 visits: 1-Screening; 2-Dental surgery (patients who have moderate to severe pain afterwards were randomised and received study drug); 3-End of study. Overall, 745 patients were enrolled (screened), of them 611 were randomized to receive the study drug and therefore considered as started.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg</title>
          <description>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="P2">
          <title>DKP-TRIS 12.5mg - TRAM.HCl 75mg</title>
          <description>DKP-TRIS 12.5mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
        </group>
        <group group_id="P3">
          <title>DKP-TRIS 25mg - TRAM.HCl 37.5mg</title>
          <description>DKP-TRIS 25mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="P4">
          <title>DKP-TRIS 25mg - TRAM.HCl 75mg</title>
          <description>DKP-TRIS 25mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
        </group>
        <group group_id="P5">
          <title>DKP-TRIS 12.5mg</title>
          <description>DKP-TRIS 12.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="P6">
          <title>DKP-TRIS 25mg</title>
          <description>DKP-TRIS 25mg oral film-coated tablet, once</description>
        </group>
        <group group_id="P7">
          <title>TRAM.HCl 37.5mg</title>
          <description>TRAM.HCl 37.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="P8">
          <title>TRAM.HCl 75mg</title>
          <description>TRAM.HCl 75mg oral film-coated tablet, once</description>
        </group>
        <group group_id="P9">
          <title>Ibuprofen 400mg</title>
          <description>Ibuprofen 400mg oral film-coated tablet, once</description>
        </group>
        <group group_id="P10">
          <title>Placebo</title>
          <description>Placebo oral film-coated tablet, once</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="61"/>
                <participants group_id="P7" count="59"/>
                <participants group_id="P8" count="60"/>
                <participants group_id="P9" count="61"/>
                <participants group_id="P10" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="61"/>
                <participants group_id="P7" count="59"/>
                <participants group_id="P8" count="60"/>
                <participants group_id="P9" count="61"/>
                <participants group_id="P10" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT (&gt;= 1 Assessment Post Randomization)</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="60"/>
                <participants group_id="P7" count="59"/>
                <participants group_id="P8" count="59"/>
                <participants group_id="P9" count="60"/>
                <participants group_id="P10" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="61"/>
                <participants group_id="P7" count="58"/>
                <participants group_id="P8" count="60"/>
                <participants group_id="P9" count="61"/>
                <participants group_id="P10" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Electronic data capture failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg</title>
          <description>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="B2">
          <title>DKP-TRIS 12.5mg - TRAM.HCl 75mg</title>
          <description>DKP-TRIS 12.5mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
        </group>
        <group group_id="B3">
          <title>DKP-TRIS 25mg - TRAM.HCl 37.5mg</title>
          <description>DKP-TRIS 25mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="B4">
          <title>DKP-TRIS 25mg - TRAM.HCl 75mg</title>
          <description>DKP-TRIS 25mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
        </group>
        <group group_id="B5">
          <title>DKP-TRIS 12.5mg</title>
          <description>DKP-TRIS 12.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="B6">
          <title>DKP-TRIS 25mg</title>
          <description>DKP-TRIS 25mg oral film-coated tablet, once</description>
        </group>
        <group group_id="B7">
          <title>TRAM.HCl 37.5mg</title>
          <description>TRAM.HCl 37.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="B8">
          <title>TRAM.HCl 75mg</title>
          <description>TRAM.HCl 75mg oral film-coated tablet, once</description>
        </group>
        <group group_id="B9">
          <title>Ibuprofen 400mg</title>
          <description>Ibuprofen 400mg oral film-coated tablet, once</description>
        </group>
        <group group_id="B10">
          <title>Placebo</title>
          <description>Placebo oral film-coated tablet, once</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="61"/>
            <count group_id="B5" value="60"/>
            <count group_id="B6" value="61"/>
            <count group_id="B7" value="59"/>
            <count group_id="B8" value="60"/>
            <count group_id="B9" value="61"/>
            <count group_id="B10" value="62"/>
            <count group_id="B11" value="611"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="7.64"/>
                    <measurement group_id="B2" value="26.9" spread="7.62"/>
                    <measurement group_id="B3" value="26.3" spread="7.33"/>
                    <measurement group_id="B4" value="27.3" spread="7.55"/>
                    <measurement group_id="B5" value="27.0" spread="9.85"/>
                    <measurement group_id="B6" value="26.9" spread="6.94"/>
                    <measurement group_id="B7" value="25.5" spread="7.15"/>
                    <measurement group_id="B8" value="27.8" spread="7.99"/>
                    <measurement group_id="B9" value="26.6" spread="6.48"/>
                    <measurement group_id="B10" value="26.1" spread="6.64"/>
                    <measurement group_id="B11" value="26.9" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="41"/>
                    <measurement group_id="B10" value="33"/>
                    <measurement group_id="B11" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="29"/>
                    <measurement group_id="B11" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index (measured in kg/m^2)</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="3.39"/>
                    <measurement group_id="B2" value="24.1" spread="3.69"/>
                    <measurement group_id="B3" value="23.0" spread="2.87"/>
                    <measurement group_id="B4" value="23.2" spread="3.19"/>
                    <measurement group_id="B5" value="23.6" spread="3.20"/>
                    <measurement group_id="B6" value="23.5" spread="3.30"/>
                    <measurement group_id="B7" value="23.0" spread="3.19"/>
                    <measurement group_id="B8" value="24.2" spread="3.08"/>
                    <measurement group_id="B9" value="22.4" spread="3.04"/>
                    <measurement group_id="B10" value="22.7" spread="2.80"/>
                    <measurement group_id="B11" value="23.3" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.</title>
        <description>Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %</description>
        <time_frame>6 hours</time_frame>
        <population>ITT (intention to treat) population which was defined as all patients who have taken the study treatment and have at least 1 post-dose assessment</population>
        <group_list>
          <group group_id="O1">
            <title>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg</title>
            <description>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O2">
            <title>DKP-TRIS 12.5mg - TRAM.HCl 75mg</title>
            <description>DKP-TRIS 12.5mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O3">
            <title>DKP-TRIS 25mg - TRAM.HCl 37.5mg</title>
            <description>DKP-TRIS 25mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O4">
            <title>DKP-TRIS 25mg - TRAM.HCl 75mg</title>
            <description>DKP-TRIS 25mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O5">
            <title>DKP-TRIS 12.5mg</title>
            <description>DKP-TRIS 12.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O6">
            <title>DKP-TRIS 25mg</title>
            <description>DKP-TRIS 25mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O7">
            <title>TRAM.HCl 37.5mg</title>
            <description>TRAM.HCl 37.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O8">
            <title>TRAM.HCl 75mg</title>
            <description>TRAM.HCl 75mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O9">
            <title>Ibuprofen 400mg</title>
            <description>Ibuprofen 400mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Placebo oral film-coated tablet, once</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.</title>
          <description>Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %</description>
          <population>ITT (intention to treat) population which was defined as all patients who have taken the study treatment and have at least 1 post-dose assessment</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="60"/>
                <count group_id="O10" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="59.7"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="72.1"/>
                    <measurement group_id="O5" value="26.7"/>
                    <measurement group_id="O6" value="55.0"/>
                    <measurement group_id="O7" value="10.2"/>
                    <measurement group_id="O8" value="25.4"/>
                    <measurement group_id="O9" value="45.0"/>
                    <measurement group_id="O10" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.</title>
        <description>Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 4, 8 and 12 hours(maxTOTPAR4h= 16, maxTOTPAR8h= 32 and maxTOTPAR12h= 48, respectively) Unit of measure is %</description>
        <time_frame>4, 8 and 12 hours</time_frame>
        <population>ITT (intention to treat) population which was defined as all patients who have taken the study treatment and have at least 1 post-dose assessment</population>
        <group_list>
          <group group_id="O1">
            <title>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg</title>
            <description>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O2">
            <title>DKP-TRIS 12.5mg - TRAM.HCl 75mg</title>
            <description>DKP-TRIS 12.5mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O3">
            <title>DKP-TRIS 25mg - TRAM.HCl 37.5mg</title>
            <description>DKP-TRIS 25mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O4">
            <title>DKP-TRIS 25mg - TRAM.HCl 75mg</title>
            <description>DKP-TRIS 25mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O5">
            <title>DKP-TRIS 12.5mg</title>
            <description>DKP-TRIS 12.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O6">
            <title>DKP-TRIS 25mg</title>
            <description>DKP-TRIS 25mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O7">
            <title>TRAM.HCl 37.5mg</title>
            <description>TRAM.HCl 37.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O8">
            <title>TRAM.HCl 75mg</title>
            <description>TRAM.HCl 75mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O9">
            <title>Ibuprofen 400mg</title>
            <description>Ibuprofen 400mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Placebo oral film-coated tablet, once</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.</title>
          <description>Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 4, 8 and 12 hours(maxTOTPAR4h= 16, maxTOTPAR8h= 32 and maxTOTPAR12h= 48, respectively) Unit of measure is %</description>
          <population>ITT (intention to treat) population which was defined as all patients who have taken the study treatment and have at least 1 post-dose assessment</population>
          <units>percentage of patient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="60"/>
                <count group_id="O10" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="72.6"/>
                    <measurement group_id="O3" value="65.1"/>
                    <measurement group_id="O4" value="78.7"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="65.0"/>
                    <measurement group_id="O7" value="11.9"/>
                    <measurement group_id="O8" value="23.7"/>
                    <measurement group_id="O9" value="56.7"/>
                    <measurement group_id="O10" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="48.4"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="54.1"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="31.7"/>
                    <measurement group_id="O7" value="6.8"/>
                    <measurement group_id="O8" value="20.3"/>
                    <measurement group_id="O9" value="33.3"/>
                    <measurement group_id="O10" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="35.5"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="37.7"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="13.3"/>
                    <measurement group_id="O7" value="5.1"/>
                    <measurement group_id="O8" value="15.3"/>
                    <measurement group_id="O9" value="25.0"/>
                    <measurement group_id="O10" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Using Rescue Medication at 6 Hours</title>
        <description>Percentage of patients using rescue medication at 6 hours post-dosing.</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>ITT (intention to treat) population which was defined as all patients who have taken the study treatment and have at least 1 post-dose assessment</population>
        <group_list>
          <group group_id="O1">
            <title>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg</title>
            <description>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O2">
            <title>DKP-TRIS 12.5mg - TRAM.HCl 75mg</title>
            <description>DKP-TRIS 12.5mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O3">
            <title>DKP-TRIS 25mg - TRAM.HCl 37.5mg</title>
            <description>DKP-TRIS 25mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O4">
            <title>DKP-TRIS 25mg - TRAM.HCl 75mg</title>
            <description>DKP-TRIS 25mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O5">
            <title>DKP-TRIS 12.5mg</title>
            <description>DKP-TRIS 12.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O6">
            <title>DKP-TRIS 25mg</title>
            <description>DKP-TRIS 25mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O7">
            <title>TRAM.HCl 37.5mg</title>
            <description>TRAM.HCl 37.5mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O8">
            <title>TRAM.HCl 75mg</title>
            <description>TRAM.HCl 75mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O9">
            <title>Ibuprofen 400mg</title>
            <description>Ibuprofen 400mg oral film-coated tablet, once</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Placebo oral film-coated tablet, once</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Using Rescue Medication at 6 Hours</title>
          <description>Percentage of patients using rescue medication at 6 hours post-dosing.</description>
          <population>ITT (intention to treat) population which was defined as all patients who have taken the study treatment and have at least 1 post-dose assessment</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="60"/>
                <count group_id="O10" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="46.8"/>
                    <measurement group_id="O3" value="39.7"/>
                    <measurement group_id="O4" value="37.7"/>
                    <measurement group_id="O5" value="65.0"/>
                    <measurement group_id="O6" value="53.3"/>
                    <measurement group_id="O7" value="69.5"/>
                    <measurement group_id="O8" value="64.4"/>
                    <measurement group_id="O9" value="48.3"/>
                    <measurement group_id="O10" value="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 ± 3 days</time_frame>
      <desc>Analyzed for the Safety population (all patients who received study treatment)</desc>
      <group_list>
        <group group_id="E1">
          <title>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg</title>
          <description>DKP-TRIS 12.5mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="E2">
          <title>DKP-TRIS 12.5mg - TRAM.HCl 75mg</title>
          <description>DKP-TRIS 12.5mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
        </group>
        <group group_id="E3">
          <title>DKP-TRIS 25mg - TRAM.HCl 37.5mg</title>
          <description>DKP-TRIS 25mg - TRAM.HCl 37.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="E4">
          <title>DKP-TRIS 25mg - TRAM.HCl 75mg</title>
          <description>DKP-TRIS 25mg - TRAM.HCl 75mg oral film-coated tablet, once</description>
        </group>
        <group group_id="E5">
          <title>DKP-TRIS 12.5mg</title>
          <description>DKP-TRIS 12.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="E6">
          <title>DKP-TRIS 25mg</title>
          <description>DKP-TRIS 25mg oral film-coated tablet, once</description>
        </group>
        <group group_id="E7">
          <title>TRAM.HCl 37.5mg</title>
          <description>TRAM.HCl 37.5mg oral film-coated tablet, once</description>
        </group>
        <group group_id="E8">
          <title>TRAM.HCl 75mg</title>
          <description>TRAM.HCl 75mg oral film-coated tablet, once</description>
        </group>
        <group group_id="E9">
          <title>Ibuprofen 400mg</title>
          <description>Ibuprofen 400mg oral film-coated tablet, once</description>
        </group>
        <group group_id="E10">
          <title>Placebo</title>
          <description>Placebo oral film-coated tablet, once</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting the results of this study for publication or presentation, the investigator will allow the Sponsor at least 60 days time to review and comment upon the publication manuscript. It is agreed, that the results of the study will not be submitted for presentation, abstract, poster exhibition, or publication by the investigator until the Sponsor has reviewed/commented and agreed to any publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Angela Capriati, Corporate Clinical Research Director</name_or_title>
      <organization>Menarini Ricerche S.p.A.</organization>
      <phone>+39 055 5680 9933</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

